世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の腫瘍壊死因子(TNF)阻害薬市場 2019-2023年

Global TNF Inhibitors Market 2019-2023

IRTNTR30008

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
122

サマリー

この調査レポートは世界の腫瘍壊死因子(TNF)阻害薬市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Tumor Necrosis Factor (TNF)
TNF is a cell signaling cytokine that is secreted by macrophages and plays a role in systemic inflammation, which is known to be the cause of various autoimmune diseases. TNF inhibitors are drugs that reverse the damage caused by these diseases.
Technavio’s analysts forecast the Global TNF Inhibitors Market to grow at a CAGR of 9.58% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the TNF inhibitors market. To calculate the market size, the report considers the revenue generated from the application of TNF inhibitors in healthcare across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, TNF inhibitors market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Amgen
- Johnson & Johnson
- Novartis
- Pfizer
- UCB
Market driver
- Increasing prevalence of autoimmune disorders
- For a full, detailed list, view our report

Market challenge
- Growing advent of biosimilars
- For a full, detailed list, view our report

Market trend
- Strategic alliances
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 08: MARKET SEGMENTATION BY INDICATION
- Market segmentation by indication
- Comparison by indication
- TNF inhibitors for RA - Market size and forecast 2018-2023
- TNF inhibitors for psoriasis - Market size and forecast 2018-2023
- TNF inhibitors for IBD - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by indication
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie
- Amgen
- Johnson & Johnson
- Novartis
- Pfizer
- UCB
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO

-
Exhibit 01: Global autoimmune drugs market
Exhibit 02: Segments of global autoimmune drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Customer landscape
Exhibit 18: Market share by geography 2018-2023 (%)
Exhibit 19: Geographic comparison
Exhibit 20: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 22: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 24: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 26: Key leading countries
Exhibit 27: Market opportunity
Exhibit 28: Indication - Market share 2018-2023 (%)
Exhibit 29: Comparison by indication
Exhibit 30: TNF inhibitors for RA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: TNF inhibitors for RA - Year-over-year growth 2019-2023 (%)
Exhibit 32: TNF inhibitors for RA - Drivers and challenges
Exhibit 33:TNF inhibitors for psoriasis -
Market size and forecast 2018-2023 ($ millions)
Exhibit 34: TNF inhibitors for psoriasis - Year-over-year growth 2019-2023 (%)
Exhibit 35:TNF inhibitors for psoriasis: Overview of market drivers and challenges
Exhibit 36:TNF inhibitors for IBD - Market size and forecast
2018-2023 ($ millions)
Exhibit 37:TNF inhibitors for IBD - Year-over-year growth 2019-2023 (%)
Exhibit 38: TNF inhibitors for IBD: Overview of market drivers and challenges
Exhibit 39:Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 40:Others - Year-over-year growth 2019-2023 (%)
Exhibit 41: Market opportunity by indication
Exhibit 42: Prevalence of arthritis in adults in the US
Exhibit 43: Growing geriatric population based on region
Exhibit 44: Percentage of geriatric population to the overall population
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Patient assistance program by pharmaceutical companies
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AbbVie - Vendor overview
Exhibit 53: AbbVie - Business segments
Exhibit 54: AbbVie - Organizational developments
Exhibit 55: AbbVie - Geographic focus
Exhibit 56: AbbVie - Segment focus
Exhibit 57: AbbVie - Key offerings
Exhibit 58: AbbVie - Key customers
Exhibit 59: Amgen - Vendor overview
Exhibit 60: Amgen - Business segments
Exhibit 61: Amgen - Organizational developments
Exhibit 62: Amgen - Geographic focus
Exhibit 63: Amgen - Segment focus
Exhibit 64: Amgen - Key offerings
Exhibit 65: Amgen - Key customers
Exhibit 66: Johnson & Johnson - Vendor overview
Exhibit 67: Johnson & Johnson - Business segments
Exhibit 68: Johnson & Johnson - Organizational developments
Exhibit 69: Johnson & Johnson - Geographic focus
Exhibit 70: Johnson & Johnson - Segment focus
Exhibit 71: Johnson & Johnson - Key offerings
Exhibit 72: Johnson & Johnson - Key customers
Exhibit 73: Novartis - Vendor overview
Exhibit 74: Novartis - Business segments
Exhibit 75: Novartis - Organizational developments
Exhibit 76: Novartis - Geographic focus
Exhibit 77: Novartis - Segment focus
Exhibit 78: Novartis - Key offerings
Exhibit 79: Novartis - Key customers
Exhibit 80: Pfizer - Vendor overview
Exhibit 81: Pfizer - Business segments
Exhibit 82: Pfizer - Organizational developments
Exhibit 83: Pfizer - Geographic focus
Exhibit 84: Pfizer - Segment focus
Exhibit 85: Pfizer - Key offerings
Exhibit 86: Pfizer - Key customers
Exhibit 87: UCB - Vendor overview
Exhibit 88: UCB - Business segments
Exhibit 89: UCB - Organizational developments
Exhibit 90: UCB - Geographic focus
Exhibit 91: UCB - Segment focus4
Exhibit 92: UCB - Key offering
Exhibit 93: UCB - Key customers
Exhibit 94: Validation techniques employed for market sizing



 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る